Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9UIS9

UPID:
MBD1_HUMAN

ALTERNATIVE NAMES:
CXXC-type zinc finger protein 3; Methyl-CpG-binding protein MBD1; Protein containing methyl-CpG-binding domain 1

ALTERNATIVE UPACC:
Q9UIS9; A4UTZ0; B4DXJ5; E9PEC5; K7ELI2; K7EQZ4; K7ESN0; O15248; O95241; Q7Z7B5; Q8N4W4; Q9UNZ6; Q9UNZ7; Q9UNZ8; Q9UNZ9

BACKGROUND:
The Methyl-CpG-binding domain protein 1 (MBD1) functions as a transcriptional repressor, targeting CpG islands in promoters where DNA methylation occurs. It recruits various factors like ATF7IP and SETDB1 to repress transcription, linking DNA methylation with histone 'Lys-9' trimethylation. MBD1's ability to silence genes through these mechanisms underscores its critical role in cellular function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Methyl-CpG-binding domain protein 1 offers a pathway to uncovering new therapeutic approaches. Its key role in the intricate process of gene silencing positions it as a target of interest for developing interventions that could modulate gene expression in disease contexts.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.